WO2016007041A1 - Универсальный кардиоплегический раствор (варианты) - Google Patents
Универсальный кардиоплегический раствор (варианты) Download PDFInfo
- Publication number
- WO2016007041A1 WO2016007041A1 PCT/RU2015/000353 RU2015000353W WO2016007041A1 WO 2016007041 A1 WO2016007041 A1 WO 2016007041A1 RU 2015000353 W RU2015000353 W RU 2015000353W WO 2016007041 A1 WO2016007041 A1 WO 2016007041A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- blood
- asystole
- cardioplegic
- liter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to medicine, namely to cardiac surgery, and can be used to protect the heart from ischemia during cardioplegia.
- ITC KP Intermittent thermal blood potassium cardioplegia
- normothermic perfusion For comparative studies, the author took as a basis the cardioplegia method described previously by AM Calafiore and co-authors (Calafiore AM, Teodori G, Mezzetti A, Bosco G, Verna AM, Di Giammarco G, et al. Intermittent antegrade warm blood cardioplegia. Ann Thorac Surg 1995 59 / 398-402), which involves the administration of a 30% pure potassium chloride solution into the cardioplegic blood line. Those. this method does not provide for the use of a specialized cardioplegic solution. Cardioplegic mixture is a combination of blood and potassium chloride.
- the disadvantage of this method is the high risk of an error in the dosage of the drug and the time of its administration. Excess potassium can lead to non-resumption of heart function, and a lack to unexpected resumption of heart contractions, depletion of energy reserves and, as a result, to myocardial ischemia. Also, the disadvantage of this method is the absence in the karyoplegic mixture additional components that protect the myocardium. This can have negative consequences when during the operation it is necessary to interrupt the flow of the cardioplegic mixture for a long time to clear the blood from the surgical field.
- the disadvantages of this method include the fact that the negative effect of hypothermia on the myocardium is not eliminated, since the blood, when cooled, ceases to properly perform its functions of maintaining acid-base and osmotic homeostasis and is not able to penetrate into the smallest capillaries due to an increase in its viscosity and interstitial edema.
- thermal blood cardioplegia An alternative to pharmacological cold crystalloid cardioplegia is thermal blood cardioplegia, which plays the main role in protecting the myocardium with the patient's own warm blood. But so far there are no well-established and obvious technical solutions for all. Some authors follow the path of a combination of “Cold” and “thermal” techniques for conducting blood cardioplegia. So, the method of NTK KP (potassium chloride injection) described in [1] should without cooling and related complications.
- NTK KP potassium chloride injection
- RU 2195878 C2 A method for protecting a patient during coronary artery bypass grafting (Regional Clinical Hospital J4 ° 1 of the Sverdlovsk Region) [2], it is proposed to maintain additional myocardial protection while maintaining normal patient body temperature due to its cooling: “the cardioplegic solution is pre-cooled to a temperature of 6-8 ° C and introduce it into the coronary bed fractionally with an interval of 25-30 minutes, while additional local cooling of the myocardium is carried out by placing in the pericardial cavity yl ice porridge. " The HKKP method described in [1] is based on the use of a crystalloid solution for cold blood cardioplegia, i.e. on mixing cold blood and a blood substitute solution.
- the article refers to “continuous warm blood cardioplegia”, the purpose of which is to prevent reperfusion damage to the myocardium before removing the clamp from the aorta. “In practice, most surgeons interrupt the perfusate flow for several minutes to apply distal anastomoses, which leads to“ unintentional ”myocardial ischemia. Another potential problem associated with the use of this technique is an overdose of cardioplegia. ” This directly indicates that the authors for "continuous cardioplegia with warm blood before removing the clamp from the aorta” do not have obvious solutions to protect the myocardium from ischemia, reperfusion injuries and hyperkalemia, which is a significant problem for this method. A similar problem is indicated in the book of J.
- the closest analogue of the invention is the drug according to the patent of the Russian Federation N ° 2145843 [5], designed for continuous blood cardioplegia.
- Two types of solution HKPN ° 1 and HKPN ° 2 (hereinafter NKR - normothermic cardioplegic solution) are described, including potassium chloride, magnesium sulfate, trometamol (trihydroxymethylaminomethane), mannitol, distilled water, differing mainly in the content of potassium chloride.
- the concentration of potassium chloride is 7.0 - 8.0 g / liter, magnesium sulfate - 2.17-2.27 g / liter, trometamol - 0.06-0.08 g / liter, mannitol ( in terms of g / liter) - 28.84-34.09 g / liter, and in HKPN ° 2 (low potassium solution), the concentration of potassium chloride is 1.91 - 2.08 g / liter, magnesium sulfate is 2.17- 2.27 g / liter, trometamol - 0.04-0.06 g / liter, mannitol - 44.57-49.83 g / liter.
- HKPN ° 1 is used for cardiac arrest, and HKPN ° 2 for maintaining asystole.
- the following working technique is described in [5]: “NKR is constantly mixed with blood from an oxygenator in a ratio of 1: 4. After clamping the aorta, NKR is injected into the heart for 6 minutes. A mixture of NKR Mel and blood is injected at a rate of 250 - 300 ml / min. To maintain asystole, they switch to the introduction of a mixture of HKPNo2 and blood at a rate of 100 - 150 ml / min, in the same ratio 1: 4. After completion of the intracardiac phase of the operation, the delivery of the NKR is stopped. ”
- HKPN ° 1 solution is the risk of difficulties in cardiac arrest
- NKRM ° 2 solution is the risk of ventricular activity of up to 2.5% and atrial activity of up to 5% of patients during the operation
- normothermic cardioplegic solution in the operation of myocardial revascularization. Thoracic and cardiovascular surgery. N ° 4, 2006, p. 5).
- HKPJ ° 1 and NKR 2 solutions are the need for a break to change the type of solution, which can lead to the resumption of heart function and adversely affect myocardial protection.
- the need for a transition from one type of solution to another arises not only during the transition to maintaining asystole at the initial stage of cardioplegia, it can also arise during the operation itself with spontaneous resumption of heart activity.
- cardioplegic compositions include potassium chloride and often magnesium sulfate. It is potassium and magnesium ions that are responsible for cardiac arrest.
- special solutions are often used to correct the pH level, increase osmolarity, normalize the ionic composition of the blood, compensate for blood loss and fill the volume of the cardiopulmonary bypass.
- These solutions may also contain various salts of potassium and magnesium.
- the content of potassium and magnesium in it is desirable to indicate not in the volume of the corresponding salts, but in the amount of potassium and magnesium ions. This simplifies the calculation of the number of ions in the blood of patients with concomitant infusion therapy.
- a high potassium HKPN ° 1 solution was prepared.
- the concentration of potassium chloride was 7.45 g / liter, magnesium sulfate - 2.2 g / liter, trometamol - 0.08 g / liter, mannitol - 30 g / liter.
- the pH was 7.7.
- the prepared solution was used for cardioplegia during coronary artery bypass surgery, and was also used to control the duration of storage of the solution.
- a shelf life of up to 12 months at room temperature was declared.
- the solution was administered at a rate of 100 - 150 ml / min and a ratio of 1: 8 with blood.
- a resumption of electromechanical activity was noted ventricles of the heart, and in three - atrial activity.
- the ratio of solution to blood was changed by 1: 2 for one minute, after which asystole was restored in all cases.
- the solution was also administered at a rate of 100-150 ml / min, but in a ratio of 1: 6 with blood. At the same time, only one patient had atrial activity.
- the ratio of solution to blood was also changed by 1: 2 for one minute, after which complete asystole was restored.
- the ratio of solution to blood was changed by 1: 2 for one minute during application of the distal anastomosis.
- the Authors increased the volume of trometamol in the range of 0.06 - 1.0 g / l in order to strengthen the pH buffer, which made it possible to compensate for the increase in the acidity of the solution during its long-term storage.
- the pH of the solution increases.
- the use for this purpose of an inorganic acid for example sulfuric acid or hydrochloric acid, requires higher accuracy when dosing.
- Organic acids, such as citric acid or acetic acid are weaker and their exact selection is simplified. But at the same time, 2 to 3 times more organic acids are required in absolute volume.
- Tromethamol used in this composition is a chemical base and can be replaced with any other pharmaceutically acceptable base. For example, if the patient has kidney or liver failure, as well as respiratory failure, it is advisable to replace trometamol with sodium bicarbonate.
- a cardioplegic solution without trometamol was prepared in which the concentration of potassium chloride was 7.45 g / liter, magnesium sulfate - 2.2 g / liter, bicarbonate -2 g / liter, mannitol - 30 g / liter. After sterilization, the pH was 7.7. Cardiac surgery was successful, and kidney function did not deteriorate.
- cardioplegic solutions are made hyperosmolar.
- mannitol is used to maintain osmolarity in the range of 407 - 425 mOsm / kg.
- hypersensitivity reactions such as anaphylactoid shock, may develop.
- other pharmaceutically acceptable diuretics for example sodium ions, glucose, dextrose, sorbitol, colloids, or a combination of these substances.
- a cardioplegic solution was prepared in which mannitol was replaced by glucose.
- the concentration of potassium chloride was 7.45 g / liter, magnesium sulfate - 2.2 g / liter, trometamol -0.08 g / liter, glucose 25 g / liter.
- Cardiac surgery was successful; no allergic reactions were detected.
- the introduction of diuretics is not recommended if the initial osmolality of the patient's blood plasma is more than 320 mOsm / kg.
- Such osmolarity indicators can occur in patients with chronic renal failure, decompensated diabetes. In these cases, it is not advisable to include diuretics in the composition of the cardioplegic solution.
- the control of the osmolarity of blood plasma is carried out by special measures, such as hemodialysis, regardless of the use of a cardioplegic solution.
- a cardioplegic solution without diuretics was prepared in which the concentration of potassium chloride was 7.45 g / liter, magnesium sulfate - 2.2 g / liter, trometamol - 0.08 g / liter. Cardiac surgery was successful, the patient did not worsen.
- a patient with hypersensitivity to magnesium sulfate was prescribed coronary artery bypass surgery.
- a cardioplegic solution was prepared without magnesium sulfate, but with a high content of potassium chloride.
- the concentration of potassium chloride in the solution was 10 g / liter, trometamol - 0.08 g / liter, mannitol - 30 g / liter.
- Cardiac surgery was successful; no allergic reactions were detected in the patient.
- He was prescribed therapy, including including intravenous administration of a 25% solution of magnesium sulfate in an amount of 20 ml. twice a day.
- a cardioplegic solution was prepared with a low magnesium sulfate content of 4 mmol / L.
- the concentration of potassium chloride in the solution was 7.45 g / liter, magnesium sulfate - 1 g / liter, trometamol - 0.08 g / liter, mannitol - 30 g / liter.
- Cardiac surgery was successful, cerebral and myocardial edema was not detected.
- a modified solution was prepared with a higher content of potassium chloride, trometamol and with the addition of hydrochloric acid.
- the concentration of potassium chloride was 8.38 g / liter, magnesium sulfate - 2.34 g / liter, trometamol - 0.5 g / liter, mannitol - 35.9 g / liter, hydrochloric acid - 3.2 ml / liter.
- the pH after sterilization was 7.8.
- the prepared solution was used for conducting cardioplegia during subsequent coronary artery bypass surgery, and was also used to control the duration of storage of the solution. With this solution, 17 operations were performed.
- the solution was initially administered in a 1: 4 ratio with blood at a rate of 250 - 300 ml / min.
- asystole occurred in the interval of 1-2 minutes, in one patient in the 4th minute.
- asystole did not occur within 4 minutes, after which the ratio of solution to blood was changed to 1: 2, after which asystole was reached within 1 minute.
- the solution was administered at a rate of 100-150 ml / min and a ratio of 1: 8 with blood. Only one patient had a resumption of the electromechanical activity of the heart, while changed the ratio of solution and blood by 1: 2 for one minute, and asystole was restored. Atrial activity was not observed.
- a solution was prepared with a low content of potassium chloride, the concentration of which was 3.0 g / liter, magnesium sulfate - 2.1 g / liter, trometamol - 0.2 g / liter, mannitol - 30 g / liter.
- Acetic acid to pH 7.2 was taken as a pharmaceutically acceptable acid. After sterilization, the pH was 7.1.
- the prepared solution was used for cardioplegia during coronary artery bypass surgery, and was also used to control the duration of storage of the solution. With this solution, 7 operations were performed.
- the solution was initially administered in a 1: 1 ratio with blood at a rate of 250 - 300 ml / min.
- a solution was prepared with a very high content of potassium chloride and a high content of trometamol.
- the concentration of potassium chloride was 15 g / liter, magnesium sulfate - 2.5 g / liter, trometamol - 1 g / liter, mannitol - 40 g / liter.
- citric acid was taken to pH 9.0.
- the pH after sterilization was 8.9.
- the prepared solution was used for cardioplegia during coronary artery bypass surgery, and was also used to control the duration of storage of the solution. With this solution, 10 operations were performed. The solution throughout the operation was administered at a rate of 100-150 ml / min ml / min.
- the solution was administered in a ratio of 1: 4 with blood. In all 10 patients, asystole occurred in the interval of 1-2 minutes. After achieving asystole, the solution was administered at a ratio of 1: 10 with blood. In this case, the resumption of ventricular and atrial activity was not observed.
- a method for changing the content of potassium chloride in a cardioplegic solution directly during the operation was tested.
- a cardioplegic solution made with a low content of potassium chloride the concentration of which was 3.0 g / liter, magnesium sulfate - 2.1 g / liter, trometamol - 0.2 g / liter, mannitol - 30 g / liter, acetic acid - 5.2 ml / liter.
- a programmable syringe dispenser was used, in which a potassium chloride solution (30%) was charged.
- the solution of potassium chloride from the syringe was dispensed into the cardioplegic line, where it was mixed with the prepared solution before being fed into the coronary bed.
- the syringe dispenser two modes of infusion were provided - to achieve asystole and maintain asystole.
- the calculated concentration of potassium chloride in the cardioplegic line was respectively 8.38 and 3.0 g / liter.
- the feed rate of the cardioplegic mixture was constant and amounted to 250 ml / min with a ratio of solution to blood 1: 4.
- the blood parameters monitors CDITM 500 made by Terumo, were used, which make it possible to obtain the content of potassium ions in real time.
- CDITM 500 made by Terumo
- the syringe dispenser was switched to the asystole maintenance mode.
- the supply of the cardioplegic mixture and the operation of infusion pumps were stopped. In this case, the resumption of ventricular and atrial activity was not observed.
- the feed rate of the cardioplegic mixture in the range of 250 - 300 ml / min provides a sufficient flow blood to the heart and provides its high-quality protection against ischemia, even in conditions of myocardial hypertrophy.
- a solution with a potassium chloride content in the range of 3 to 9 g / liter is preferred. But such a flow rate of the solution may be unacceptable for some pathologies of the myocardium or pediatric cardiac surgery, since it can cause damage to the myocardium.
- a high solution feed rate also leads to an increase in hemodilution, which may be undesirable under certain conditions.
- a solution with a high potassium chloride content in the range of 9 to 15 g / liter is preferred.
- the quantitative ratio of the components of the solution is significantly affected by its ratio to blood. The ratio is 1: 4, since there is enough blood to ensure myocardial protection and the cardioplegic solution is presented in sufficient volume. This ratio allows for prolonged cardioplegia with the necessary protection of the myocardium.
- this ratio can be safely reduced in the range from 1: 4 to 1: 1 in order to accelerate the achievement of asystole or saturation of the myocardium with the components of the solution before stopping the flow of the cardioplegic mixture to clean the surgical field.
- An increase in the ratio of solution and blood from 1: 4 to 1: 10 is necessary when using the same solution to maintain the previously achieved asystole.
- an effective solution can be to use a low potassium universal solution and a syringe dispenser with a solution of potassium chloride to change the concentration of potassium chloride in the supplied mixture of blood and cardioplegic solution.
- the described method of using a cardioplegic solution can be most effectively used in normothermia, when the solution itself, the heart and the patient’s body are not cooled. Moreover, in terms of the use of universal cardioplegic solution during surgery, there are no restrictions on the duration of cardioplegia due to the absence of ischemia and reperfusion injuries during and after it. This indication helps to reduce complications during operations, expands indications for operations in cardiopulmonary bypass patients who are denied cardiac surgery in conditions of hypothermia.
- This cardioplegic solution can also be used in conditions of hypothermia in cases where hypothermia is a traditional or mandatory practice in a cardioclinic, or in case of an emergency during the operation, when a long interruption in the supply of cardioplegic mixture is necessary.
- hypothermia is a traditional or mandatory practice in a cardioclinic, or in case of an emergency during the operation, when a long interruption in the supply of cardioplegic mixture is necessary.
- the use of superficial (31-35 ° C) and moderate (25-30 ° C) hypothermia is recommended, since with a deeper cooling of the cardioplegic solution, the protective properties of the blood deteriorate.
- the technical result of the invention is to increase myocardial protection, expand indications for operations and reduce mortality during cardiac operations in cardiopulmonary bypass using cardioplegia, as well as the versatility of cardioplegic solution.
- the subject of this invention is a new universal cardioplegic solution, which contains the following pharmaceutically acceptable components:
- the base may be any pharmaceutically acceptable base, for example trometamol or sodium bicarbonate;
- the acid is one or more pharmaceutically acceptable acids selected from the group of organic or inorganic acids, for example sulfuric acid, hydrochloric acid, citric acid, acetic acid.
- the subject of this invention is a new universal cardioplegic solution, which contains the following pharmaceutically acceptable components:
- a pharmaceutically acceptable diuretic providing an osmolality between 275 and 460 mOsm / kg .
- the diuretic may be any pharmaceutically acceptable diuretic, for example mannitol, glucose, dextrose, sorbitol.
- the preferred composition for universal cardioplegic solution contains the components:
- composition for universal cardioplegic solution contains the components:
- solution B The main difference between solution B and solution A is a higher concentration of potassium chloride, which with equal volumes of cardioplegic mixture provides faster asystole, but requires more attention to the volume of the injected solution in order to prevent hyperkalemia.
- solution A reduces the risk of hyperkalemia, but increases the risk of longer cardiac arrest and fibrillation.
- the choice of a specific method for changing the level of potassium in a cardioplegic mixture depends on the stage of cardioplegia, the experience of the surgical team and the availability of the necessary perfusion equipment and equipment for mixing the solution components.
- the ratio of cardioplegic solution and blood should vary from 1: 1 to 1: 4, while asystole will also be confidently achieved.
- the ratio of cardioplegic solution and blood should accordingly vary from 1: 4 to 1: 10;
- the indicated components of the solution within the indicated concentrations per 1 liter can effectively solve the problems of cardioplegia and provide protective functions, including: maintaining the pumping function of the heart, eliminating acidosis, maintaining the pH level, preventing myocardial and cerebral edema.
- blood performs other necessary functions to protect the myocardium: it supplies oxygen and nutrients, removes oxidation products, and provides protection against bacterial and viral infections. It is the use of blood that relieves restrictions on the duration of the operation using a universal cardioplegic solution.
- the ratio of the components of the solution and blood can vary from 1: 1 to 1: 10. This ratio is determined depending on the concentration of potassium in the initial solution and the problem to be solved at a particular stage of cardioplegia. As a rule, cardioplegia begins with a ratio of the components of the solution and blood 1: 4. In the future, if it is necessary to accelerate the onset of asystole or before a break in the supply of a cardioplegic mixture, this ratio can be increased, but not more than up to 1: 1. After reaching asystole, or before the end of cardioplegia, this ratio can be reduced, but not less than 1: 10.
- Figure 1 The scheme of using a universal cardioplegic solution using a roller pump of a cardiopulmonary bypass (AIC).
- AIC cardiopulmonary bypass
- AIC cardiopulmonary bypass
- Figure 2 The scheme of using a universal cardioplegic solution when changing the content of potassium chloride in it using a syringe dispenser during the operation.
- Fig.Z The scheme of using a universal cardioplegic solution using a syringe dispenser.
- the osmolality is 440 mOsm / kg.
- perfusion is carried out maintaining the temperature of the body and heart in the range of 25 - 37 ° ⁇ (optimal temperature is 36 - 37 ° ⁇ ).
- the initial solution is constantly mixed with autoblood from the oxygenator in a ratio of 1: 4.
- RBM is injected into the aortic root or directly into the mouth of the coronary arteries, maintaining the pressure during administration of the mixture - not more than 100 mm Hg. at the root of the aorta.
- RBM is injected into the heart for 5 minutes until a stable cardiac arrest is achieved.
- RBM is administered at a rate of 200 to 350 ml / min.
- RBM is injected into the aortic root or directly into the mouth of the coronary arteries, maintaining the pressure when the mixture is introduced - no more than 100 mmHg. in the aortic root, or in the coronary sinus, maintaining pressure with the introduction of RBM - no more than 50 mm Hg
- the time of administration, indicators of the volumetric rate of administration of RBM and the ratio of the initial solution and autologous blood from the oxygenator are determined depending on the concentration of potassium in the patient’s blood before surgery, the size and weight of his heart. After passing through the heart, U P enters the general bloodstream. After completion of the intracardiac phase of the operation, the delivery of RBM is stopped.
- a solution of potassium chloride (30%) is charged into the syringe dispenser.
- perfusion is carried out maintaining the temperature of the body and heart in the range of 25 - 37 ° ⁇ (optimal temperature is 36 - 37 ° ⁇ ).
- the initial solution is constantly mixed with autoblood from the oxygenator in a ratio of 1: 5.
- RBM is injected into the aortic root or directly into the mouth of the coronary arteries, maintaining a constant pressure with the introduction of the mixture - not more than 100 mm Hg. at the root of the aorta.
- the feed rate of the potassium chloride solution from the syringe dispenser is set so that the concentration in the cardioplegic line is 8.0 g / liter.
- the solution is supplied from the dispenser syringe for 5 minutes until a stable cardiac arrest is achieved.
- the flow of solution from the syringe dispenser stops, and the flow of RBM continues.
- the supply of RBM can be suspended if it is necessary to clean the surgical field for up to 20 minutes.
- potassium chloride supply from the dispenser syringe is turned on until the cardiac activity ceases completely. After passing through the heart, RBM falls into total blood flow. After completion of the intracardiac phase of the operation, the supply of U P is stopped.
- Citric acid 1M - up to pH 8.9
- the first introduction of RBM is performed from the moment of clamping the aorta for 3-4 minutes and is prolonged for 1 min after cardiac arrest to achieve stable asystole.
- the volumetric feed rate of the initial solution is from 40 to 70 ml / min from the syringe dispenser, and the rate of autologous blood from the AIK oxygenator is from 160 to 280 ml / min
- the volumetric flow rate of RBM decreases. The objective of this stage is to maintain a stable asystole.
- the volumetric feed rate of the initial solution with a syringe dispenser is reduced to 6-17 ml / min while reducing to 48-136 ml / min the volumetric flow rate of oxygenated autologous blood supplied by the AIK roller pump in a ratio of 1: 8 to 1 :10.
- the time of administration, indicators of volumetric rate of administration of RBM and the ratio of the initial solution and blood from an oxygenator, is determined depending on the concentration of potassium in the patient’s blood before surgery, the size and weight of his heart.
- RBM is injected into the aortic root or directly into the mouth of the coronary arteries, maintaining the pressure when the mixture is introduced - no more than 100 mmHg. in the aortic root, or in the coronary sinus, maintaining the pressure during the introduction of the mixture is not more than 50 mm Hg.
- the invention can be used in medicine and veterinary medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201700032A EA035702B1 (ru) | 2014-07-11 | 2015-06-05 | Универсальный кардиоплегический раствор (варианты) |
US15/325,501 US10646511B2 (en) | 2014-07-11 | 2015-06-05 | Universal cardioplegic solution (variants) |
JP2017522314A JP6629850B2 (ja) | 2014-07-11 | 2015-06-05 | 汎用心停止液(変種) |
BR112017000052-0A BR112017000052B1 (pt) | 2014-07-11 | 2015-06-05 | Soluções cardioplégicas para alcançar e para manter a assistolia alcançada em cardioplegia sanguínea |
CN202211187936.0A CN115813947A (zh) | 2014-07-11 | 2015-06-05 | 通用心脏麻痹液(多种变型) |
ES15819585T ES2713434T3 (es) | 2014-07-11 | 2015-06-05 | Solución cardiopléjica universal (variantes) |
CN201580037619.2A CN106659677A (zh) | 2014-07-11 | 2015-06-05 | 通用心脏麻痹液(多种变型) |
MX2017000438A MX2017000438A (es) | 2014-07-11 | 2015-06-05 | Solucion cardioplejica de propositos generales (variantes). |
EP15819585.9A EP3167874B1 (en) | 2014-07-11 | 2015-06-05 | Universal cardioplegic solution (variants) |
US16/843,376 US10987378B2 (en) | 2014-07-11 | 2020-04-08 | Universal cardioplegic solution (variants) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014128455/15A RU2574957C1 (ru) | 2014-07-11 | Кардиоплегический раствор (варианты) | |
RU2014128455 | 2014-07-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/325,501 A-371-Of-International US10646511B2 (en) | 2014-07-11 | 2015-06-05 | Universal cardioplegic solution (variants) |
US16/843,376 Division US10987378B2 (en) | 2014-07-11 | 2020-04-08 | Universal cardioplegic solution (variants) |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016007041A1 true WO2016007041A1 (ru) | 2016-01-14 |
Family
ID=55064554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2015/000353 WO2016007041A1 (ru) | 2014-07-11 | 2015-06-05 | Универсальный кардиоплегический раствор (варианты) |
Country Status (10)
Country | Link |
---|---|
US (2) | US10646511B2 (ru) |
EP (1) | EP3167874B1 (ru) |
JP (1) | JP6629850B2 (ru) |
CN (2) | CN115813947A (ru) |
BR (1) | BR112017000052B1 (ru) |
EA (1) | EA035702B1 (ru) |
ES (1) | ES2713434T3 (ru) |
MX (1) | MX2017000438A (ru) |
TR (1) | TR201901995T4 (ru) |
WO (1) | WO2016007041A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201600120839A1 (it) * | 2016-12-01 | 2018-06-01 | Valentina Valenti | Soluzione cardioplegica con attivatori dell'autofagia per l'arresto diastolico del cuore in corso di interventi cardiochirurgici |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016007041A1 (ru) | 2014-07-11 | 2016-01-14 | Общество С Ограниченной Ответственностью "Кардиосистемфарма" (Ооо "Ксф") | Универсальный кардиоплегический раствор (варианты) |
CN113795247B (zh) * | 2018-12-14 | 2024-04-05 | 陈益祥 | 用于心脏手术的稳定心脏麻痹液 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BG52177B2 (en) * | 1986-02-11 | 1998-06-30 | Стефан Н. Найденов | Cardioplegic solution |
RU2145843C1 (ru) * | 1997-06-16 | 2000-02-27 | Вольгушев Валентин Евгеньевич | Нормотермический кардиоплегический раствор |
RU2161405C2 (ru) * | 1994-12-12 | 2001-01-10 | Шарлотт-Мекленбург Хоспитал Асорити Дуинг Бизнесс эз Каролинас Медикал Сентер | Растворы для трансплантатов органов и способ трансплантации органа |
RU2226093C1 (ru) * | 2002-11-05 | 2004-03-27 | Российский кардиологический научно-производственный комплекс Министерства здравоохранения РФ | Кардиоплегический раствор "инфузол" |
US20110020475A1 (en) * | 2006-03-15 | 2011-01-27 | Universitat Bern | Cardioplegic solution |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2066374C (en) * | 1991-04-19 | 2002-01-29 | Paul E. Segall | Solution for perfusing primates |
US5306711A (en) * | 1992-06-24 | 1994-04-26 | Georgetown University | Organ preservative solution |
US5405742A (en) | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
US5656420A (en) | 1995-02-24 | 1997-08-12 | University Of Kentucky Research Foundation | Method for employing the delta opioid dadle to extend tissue survival time during ischemia |
US6492103B1 (en) | 2000-01-31 | 2002-12-10 | Organ Recovery Systems, Inc. | System for organ and tissue preservation and hypothermic blood substitution |
SE0002832D0 (sv) * | 2000-08-07 | 2000-08-07 | Jostra Ab | Cardioplegic solution |
RU2195878C2 (ru) | 2000-09-21 | 2003-01-10 | Областная клиническая больница № 1 Свердловской области | Способ защиты больного при проведении операций аортокоронарного шунтирования |
AU2009215884A1 (en) * | 2008-02-15 | 2009-08-27 | President And Fellows Of Harvard College | Cardioplegia solution for cardiac surgery |
RU2413502C1 (ru) * | 2009-07-24 | 2011-03-10 | Учреждение Российской академии медицинских наук Научный центр сердечно-сосудистой хирургии им. А.Н. Бакулева РАМН | Кардиоплегический раствор "асн-бокерия-болдырева" |
WO2016007041A1 (ru) | 2014-07-11 | 2016-01-14 | Общество С Ограниченной Ответственностью "Кардиосистемфарма" (Ооо "Ксф") | Универсальный кардиоплегический раствор (варианты) |
-
2015
- 2015-06-05 WO PCT/RU2015/000353 patent/WO2016007041A1/ru active Application Filing
- 2015-06-05 US US15/325,501 patent/US10646511B2/en active Active
- 2015-06-05 TR TR2019/01995T patent/TR201901995T4/tr unknown
- 2015-06-05 JP JP2017522314A patent/JP6629850B2/ja active Active
- 2015-06-05 MX MX2017000438A patent/MX2017000438A/es unknown
- 2015-06-05 EA EA201700032A patent/EA035702B1/ru unknown
- 2015-06-05 ES ES15819585T patent/ES2713434T3/es active Active
- 2015-06-05 BR BR112017000052-0A patent/BR112017000052B1/pt active IP Right Grant
- 2015-06-05 EP EP15819585.9A patent/EP3167874B1/en active Active
- 2015-06-05 CN CN202211187936.0A patent/CN115813947A/zh active Pending
- 2015-06-05 CN CN201580037619.2A patent/CN106659677A/zh active Pending
-
2020
- 2020-04-08 US US16/843,376 patent/US10987378B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BG52177B2 (en) * | 1986-02-11 | 1998-06-30 | Стефан Н. Найденов | Cardioplegic solution |
RU2161405C2 (ru) * | 1994-12-12 | 2001-01-10 | Шарлотт-Мекленбург Хоспитал Асорити Дуинг Бизнесс эз Каролинас Медикал Сентер | Растворы для трансплантатов органов и способ трансплантации органа |
RU2145843C1 (ru) * | 1997-06-16 | 2000-02-27 | Вольгушев Валентин Евгеньевич | Нормотермический кардиоплегический раствор |
RU2226093C1 (ru) * | 2002-11-05 | 2004-03-27 | Российский кардиологический научно-производственный комплекс Министерства здравоохранения РФ | Кардиоплегический раствор "инфузол" |
US20110020475A1 (en) * | 2006-03-15 | 2011-01-27 | Universitat Bern | Cardioplegic solution |
Non-Patent Citations (1)
Title |
---|
See also references of EP3167874A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201600120839A1 (it) * | 2016-12-01 | 2018-06-01 | Valentina Valenti | Soluzione cardioplegica con attivatori dell'autofagia per l'arresto diastolico del cuore in corso di interventi cardiochirurgici |
Also Published As
Publication number | Publication date |
---|---|
BR112017000052A2 (pt) | 2017-11-07 |
JP6629850B2 (ja) | 2020-01-15 |
TR201901995T4 (tr) | 2019-03-21 |
US10646511B2 (en) | 2020-05-12 |
EP3167874A1 (en) | 2017-05-17 |
US10987378B2 (en) | 2021-04-27 |
MX2017000438A (es) | 2017-08-16 |
EA201700032A1 (ru) | 2017-05-31 |
JP2017520629A (ja) | 2017-07-27 |
EA035702B1 (ru) | 2020-07-28 |
EP3167874A4 (en) | 2017-12-27 |
US20200230171A1 (en) | 2020-07-23 |
US20170143760A1 (en) | 2017-05-25 |
CN106659677A (zh) | 2017-05-10 |
BR112017000052B1 (pt) | 2022-09-13 |
ES2713434T3 (es) | 2019-05-21 |
RU2014128455A (ru) | 2016-02-10 |
CN115813947A (zh) | 2023-03-21 |
EP3167874B1 (en) | 2018-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bartlett et al. | Current status of extracorporeal life support (ECMO) for cardiopulmonary failure | |
Montisci et al. | Management of refractory hypoxemia during venovenous extracorporeal membrane oxygenation for ARDS | |
US10987378B2 (en) | Universal cardioplegic solution (variants) | |
Monk | Acute normovolemic hemodilution | |
WO2012154220A2 (en) | Method of resuscitation | |
Lehmann et al. | Extracorporeal membrane oxygenation: experience in acute graft failure after heart transplantation | |
Shiroishi | Myocardial protection: the rebirth of potassium-based cardioplegia. | |
Ginther et al. | Use of del Nido cardioplegia solution and a low-prime recirculating cardioplegia circuit in pediatrics | |
RU2574957C1 (ru) | Кардиоплегический раствор (варианты) | |
Alibrahim et al. | Extracorporeal life support: four decades and counting | |
Pezzi et al. | Liver rupture after cardiopulmonary resuscitation (CPR) and thrombolysis | |
EP1307209B1 (en) | Cardioplegic solution | |
Nagata et al. | Anesthetic management of a patient with deteriorated cardiac function following cardiopulmonary resuscitation | |
Lefemine et al. | Concepts in assisted circulation | |
Molina et al. | Pressurized rapid cardioplegia versus administration of exogenous substrate and topical hypothermia | |
Kim et al. | Successful management of potential non-heart-beating donor with extracorporeal membrane oxygenation: A case report | |
Mama | Anesthesia for cardiopulmonary bypass | |
RU2571058C1 (ru) | Способ проведения кардиоплегии (варианты) | |
Durantaş et al. | Our Anesthesia Management in Laparoscopic Cholecystectomy of a Patient With a Left Ventricular Assist Device. | |
Vegas | Weaning from CPB | |
Singh et al. | Use of integrated extracorporeal membrane oxygenator in anomalous left coronary artery to pulmonary artery: Better survival benefit | |
Amberman et al. | Minimizing reperfusion injuries: successful resuscitation using eCPR after cardiac arrest on a post-operative Norwood patient | |
Manickam et al. | Extracorporeal Membrane Oxygenation in Respiratory Diseases in Adults | |
Ikeda | Exsanguination cooling | |
Novotny et al. | Can profound hypernatremic dehydration ever be a good thing? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15819585 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017522314 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/000438 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15325501 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017000052 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201700032 Country of ref document: EA |
|
REEP | Request for entry into the european phase |
Ref document number: 2015819585 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015819585 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112017000052 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170102 |